APR 22, 2019 8:30 PM PDT

New Oral Drug for Multiple Sclerosis Treatment

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration has approved a new oral drug for the treatment of multiple sclerosis (MS)--a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts brain communication. Individuals with MS experience their first symptoms between the ages of 20 and 40. The disease is among the most common causes of neurological disability in young adults and most frequently strikes women more than men.

The approved drug is called Mayzent (siponimod) and comes in the form of tablets prescribed to adults with relapsing forms of multiple sclerosis (MS)—which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

“Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “We are committed to continuing to work with companies that are developing additional treatment options for patients with multiple sclerosis.”

MS often begins with a relapsing-remitting course which involves episodes of relapses followed by remissions—which often leave patients with some degree of disability. Although not all patients experience some form of persistent disability, many do and will gradually worsen over time.

The disability in some patients may continue independent of relapses which is known as secondary progressive multiple sclerosis (SPMS). When patients continue to experience relapse during SPMS, this becomes a phase described as active SPMS which is one of the relapsing forms of MS. Although current drugs approved for the treatment of relapsing forms of MS can used to treat symptoms of active SPMS, disability continues to progress--another phase called non-active SPMS.

For Mayzent, the efficacy was confirmed in a clinical trial of 1,651 patients that was compared to a placebo in patients with SPMS who had disability progression in the prior two years with no relapses. Mayzent was found to decrease the progression of disability along with reducing the number of relapses experienced by MS patients. However, in individuals with non-active SPMS, results were found not to be statistically significant.

The FDA granted approval of Mayzent to Novartis.

Source: FDA

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 23, 2019
Technology
NOV 23, 2019
Can artificial intelligence increase tuberculosis drug development?
It’s no secret that there is a shortage of tuberculosis drug development. To combat this issue, researchers at the University of Michigan designed a ...
NOV 24, 2019
Drug Discovery & Development
NOV 24, 2019
The unlikely pain killer
Pain can be anything a sunburn, a toothache, or a leg injury to name a few. The relievers that target our pain come in many colors—one being morphine...
DEC 27, 2019
Drug Discovery & Development
DEC 27, 2019
New Drug to Treat Migraines Approved by FDA
Over 1 in 10 people around the world- or 780 million people. Three times more common in women than in men, until now, most treatments have been preventativ...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
FDA Approves Drugs Faster than Ever- But is That Good?
The Food and Drug Administration (FDA) is approving new drugs for patients on less and less evidence thanks to special programs that streamline their appro...
JAN 18, 2020
Drug Discovery & Development
JAN 18, 2020
Drug Combo Targets Osteoarthritis
Individuals suffering from osteoarthritis often face challenges of limited treatment options mainly pain relievers or joint replacement surgery. However, s...
Loading Comments...